Development and validation of a composite disease activity score for juvenile idiopathic arthritis
Arthritis Care & Research · 15.05.2009 · 61 (5) · 658-666
DOI: 10.1002/art.24516 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Arthritis Care & Research, online erschienen am 29.04.2009. Verfasst von Alessandro Consolaro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genoa, and the Università degli Studi di Verona, Verona, Italy. Hauptthemen laut MEDLINE: Disability Evaluation, Severity of Illness Index. Die Arbeit wurde bisher 659-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective
To develop and validate a composite disease activity score for juvenile idiopathic arthritis (JIA), the Juvenile Arthritis Disease Activity Score (JADAS).
Methods
The JADAS includes 4 measures: physician global assessment of disease activity, parent/patient global assessment of well‐being, active joint count, and erythrocyte sedimentation rate. These variables are part of the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30), Pedi 50, and Pedi 70 criteria for improvement. Validation analyses were conducted on >4,500 patients and included assessment of construct validity, discriminant validity, and responsiveness to change. Three versions of the JADAS were tested based on 71‐joint (range 0–101), 27‐joint (range 0–57), or 10‐joint (range 0–40) counts. Statistical performances of the JADAS were compared with those of 2 rheumatoid arthritis composite scores, the Disease Activity Score in 28 joints (DAS28) and the Clinical Disease Activity Index (CDAI).
Results
The JADAS demonstrated good construct validity, yielding strong correlations with JIA activity measures not included in the score and moderate correlations with the Childhood Health Assessment Questionnaire. Correlations obtained for the 3 JADAS versions were comparable, but superior to those yielded by the DAS28 and CDAI. The area under the curve of the JADAS predicted long‐term disease outcome, measured as radiographic progression over 3 years. In 2 clinical trials, the JADAS discriminated well between ACR Pedi 30, Pedi 50, and Pedi 70 response and revealed strong responsiveness to clinical change.
Conclusion
The JADAS was found to be a valid instrument for assessment of disease activity in JIA and is potentially applicable in standard clinical care, observational studies, and clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genoa, and the Università degli Studi di Verona, Verona, Italy.
Zitieren
APA
Consolaro, A., Ruperto, N., Bazso, A., Pistorio, A., Magni-Manzoni, S., Filocamo, G., Malattia, C., Viola, S., Martini, A., Ravelli, A., & Paediatric Rheumatology International Trials Organisation (2009). Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Care & Research, 61(5), 658-666. https://doi.org/10.1002/art.24516
Vancouver
Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Care & Research. 2009;61(5):658-666. doi:10.1002/art.24516
BibTeX
@article{Consolaro2009,
author = {Consolaro, Alessandro and Ruperto, Nicolino and Bazso, Anna and Pistorio, Angela and Magni-Manzoni, Silvia and Filocamo, Giovanni and Malattia, Clara and Viola, Stefania and Martini, Alberto and Ravelli, Angelo and Paediatric Rheumatology International Trials Organisation, Paediatric Rheumatology International Trials Organisation},
title = {Development and validation of a composite disease activity score for juvenile idiopathic arthritis},
journal = {Arthritis Care & Research},
year = {2009},
volume = {61},
number = {5},
pages = {658--666},
doi = {10.1002/art.24516}
}
EUVIMED